Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.

Li R. et al, (2024), Sci Transl Med, 16

Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.

Godfrey AL. et al, (2024), Br J Haematol

Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.

Carrelha J. et al, (2024), Nat Immunol, 25, 1007 - 1019

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.

Gerds AT. et al, (2024), Blood Adv

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.

Oh ST. et al, (2024), EJHaem, 5, 105 - 116

Backtracking to the future: unraveling the origins of childhood leukemia.

de Smith AJ. et al, (2023), Leukemia

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.

Brierley CK. et al, (2023), bioRxiv

Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner

Luis TC. et al, (2023), Nature Communications, 14

The management of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), Br J Haematol

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.

Fang Z. et al, (2023), Nat Commun, 14

Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.

Rampotas A. et al, (2023), Blood

Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells.

Matsuoka S. et al, (2023), Blood, 142, 1622 - 1632

Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

McLornan DP. et al, (2023), Br J Haematol

Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts.

Moura PL. et al, (2023), Cancer Res

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.

Mesa RA. et al, (2023), Hemasphere, 7

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

O'Sullivan JM. et al, (2023), Leukemia

Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner.

Luis TC. et al, (2023), Nat Commun, 14

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.

Rodriguez-Meira A. et al, (2023), Nat Genet, 55, 1531 - 1541

Systemically produced Kit ligand is sufficient to maintain mouse hematopoietic stem cells

NERLOV C. et al, (2023), Blood

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.

Harrison C. et al, (2023), Haematologica, 108, 1960 - 1964

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?